Promoter methylation‑associated silencing of p27kip1 gene with metastasis in esophageal squamous cell carcinoma

Ling,Yang; Zhang,Changsong; Xu,Yun; Zhu,Jing; Zhu,Changtai; Lu,Mingzhu; Liu,Yongping; Zhou,Tianbao

doi:10.3892/mmr.2014.1887

Promoter methylation‑associated silencing of p27kip1 gene with metastasis in esophageal squamous cell carcinoma

Authors:
- Yang Ling
- Changsong Zhang
- Yun Xu
- Jing Zhu
- Changtai Zhu
- Mingzhu Lu
- Yongping Liu
- Tianbao Zhou
View Affiliations

Affiliations: Clinical Oncology Laboratory, Changzhou Tumor Hospital, Medical College of Soochow University, Changzhou, Jiangsu 213001, P.R. China, Department of Oncology, Nanyang Center Hospital, Nanyang, Henan 473000, P.R. China, The Hepatobiliary Surgery Center, The Affiliated Ningbo No. 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang 315010, P.R. China
Published online on: January 8, 2014 https://doi.org/10.3892/mmr.2014.1887
Pages: 1075-1079

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the frequency of p27kip1 promoter methylation in esophageal squamous cell carcinoma (ESCC). The methylation status of the p27kip1 promoter was analyzed by methylation‑specific polymerase chain reaction (MSP) in 50 ESCC and matched non‑tumor tissues. Cell lines were treated with the demethylation agent 5‑aza‑2'‑deoxycytidine (5‑Aza‑CdR) and p27kip1 mRNA expression was detected by quantitative polymerase chain reaction. p27kip1 methylation was found in 36% (18/50) of ESCC patients, but only in 12% (6/50) of the corresponding non‑tumor tissues (P=0.005). There were statistically significant associations between the presence of methylation and tumor metastasis (P=0.002). The p27kip1 mRNA was lower in ESCC compared with non‑tumor tissues (mean ± standard deviation, ‑0.886±3.298 vs. 0.988±0.257; P=0.0033). Furthermore, a significant association was identified between the methylation status of the p27kip1 promoter and p27kip1 mRNA expression in the tissue (P<0.01). Thus, demethylation by 5‑Aza‑CdR was capable of inducing p27kip1 mRNA expression in esophageal cancer cell lines. The high promoter methylation of p27kip1 is a common phenomenon in ESCC, which may be an important mechanism of silencing p27kip1 mRNA expression.

View Figures

View References

1	Hongo M, Nagasaki Y and Shoji T: Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 24:729–735. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
3	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
4	Bagui TK, Cui D, Roy S, et al: Inhibition of p27Kip1 gene transcription by mitogens. Cell Cycle. 8:115–124. 2009. View Article : Google Scholar : PubMed/NCBI
5	Li H, Collado M, Villasante A, et al: p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell. 11:845–852. 2012. View Article : Google Scholar : PubMed/NCBI
6	Garcia-Fernández RA, García-Palencia P, Sánchez MA, et al: Combined loss of p21(waf1/cip1) and p27(kip1) enhances tumorigenesis in mice. Lab Invest. 91:1634–1642. 2011.PubMed/NCBI
7	Clurman BE and Porter P: New insights into the tumor suppression function of P27(kip1). Proc Natl Acad Sci USA. 95:15158–15160. 1998. View Article : Google Scholar : PubMed/NCBI
8	Viglietto G, Motti ML and Fusco A: Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle. 1:394–400. 2002. View Article : Google Scholar : PubMed/NCBI
9	Singh SP, Lipman J, Goldman H, et al: Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma. Cancer Res. 58:1730–1735. 1998.
10	Nitti D, Belluco C, Mammano E, et al: Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol. 81:167–176. 2002. View Article : Google Scholar : PubMed/NCBI
11	Zheng JY, Wang WZ, Li KZ, Guan WX and Yan W: Effect of p27(KIP1) on cell cycle and apoptosis in gastric cancer cells. World J Gastroenterol. 11:7072–7077. 2005.PubMed/NCBI
12	Heyn H and Esteller M: DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 13:679–692. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q and Zhang HX: Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol. 11:4587–4591. 2005.PubMed/NCBI
14	Qian X, Jin L, Kulig E and Lloyd RV: DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol. 153:1475–1482. 1998. View Article : Google Scholar : PubMed/NCBI
15	Serres MP, Kossatz U, Chi Y, Roberts JM, Malek NP and Besson A: p27(Kip1) controls cytokinesis via the regulation of citron kinase activation. J Clin Invest. 122:844–858. 2012. View Article : Google Scholar : PubMed/NCBI
16	Jäkel H, Peschel I, Kunze C, Weinl C and Hengst L: Regulation of p27 (Kip1) by mitogen-induced tyrosine phosphorylation. Cell Cycle. 11:1910–1917. 2012.PubMed/NCBI
17	Zhang C, Ling Y, Xu Y, et al: The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci. 8:451–458. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ling Y, Huang G, Fan L, et al: CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol. 64:246–251. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kim YK, Yu J, Han TS, et al: Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hitomi M, Yang K, Guo Y, Fretthold J, Harwalkar J and Stacey DW: p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle. 5:2281–2289. 2006. View Article : Google Scholar : PubMed/NCBI
21	Vervoorts J and Lüscher B: Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci. 65:3255–3264. 2008. View Article : Google Scholar : PubMed/NCBI
22	Hengst L and Reed SI: Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol. 227:25–41. 1998.PubMed/NCBI
23	Blain SW and Massagué J: Breast cancer banishes p27 from nucleus. Nat Med. 8:1076–1078. 2002. View Article : Google Scholar : PubMed/NCBI
24	Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149–1163. 1995. View Article : Google Scholar : PubMed/NCBI
25	Slingerland J and Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 183:10–17. 2000. View Article : Google Scholar : PubMed/NCBI
26	Tong Q, Zhang W, Jin S, Li S and Chen Z: The relationship between p27(kip1) expression and the change of radiosensitivity of esophageal carcinoma cells. Scand J Gastroenterol. 46:173–176. 2011. View Article : Google Scholar : PubMed/NCBI
27	Sgambato A, Cittadini A, Faraglia B and Weinstein IB: Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol. 183:18–27. 2000. View Article : Google Scholar : PubMed/NCBI
28	Chu IM, Hengst L and Slingerland JM: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lee J and Kim SS: The function of p27 KIP1 during tumor development. Exp Mol Med. 41:765–771. 2009. View Article : Google Scholar : PubMed/NCBI